Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-Analysis
<b>Background</b>: Numerous studies have explored the potential of the biomarker copeptin (CPP) in diagnosing and assessing the severity of chronic kidney disease (CKD). Despite these efforts, findings have been inconsistent. Consequently, this study aimed to examine the association betw...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/6/845 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850156026546880512 |
|---|---|
| author | Gabi Gazi Robert Cristian Cruciat Daniel-Corneliu Leucuta Nahlah Al Srouji Stefan-Lucian Popa Mohamed Ismaiel Dinu Iuliu Dumitrascu Abdulrahman Ismaiel |
| author_facet | Gabi Gazi Robert Cristian Cruciat Daniel-Corneliu Leucuta Nahlah Al Srouji Stefan-Lucian Popa Mohamed Ismaiel Dinu Iuliu Dumitrascu Abdulrahman Ismaiel |
| author_sort | Gabi Gazi |
| collection | DOAJ |
| description | <b>Background</b>: Numerous studies have explored the potential of the biomarker copeptin (CPP) in diagnosing and assessing the severity of chronic kidney disease (CKD). Despite these efforts, findings have been inconsistent. Consequently, this study aimed to examine the association between CPP and CKD, specifically evaluating its diagnostic value and correlation with CKD severity as classified by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines. <b>Methods</b>: A systematic search of PubMed, EMBASE, and Scopus was conducted using a predefined search string to identify relevant studies. Eligible studies included those involving CKD patients classified by glomerular filtration rate (GFR) according to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines or by the estimated GFR (eGFR) calculated using the MDRD formula, provided they met predefined inclusion criteria. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). The primary outcome measured was the mean difference (MD) in serum CPP levels across the various stages of CKD. <b>Results</b>: A total of seven studies, comprising 2769 participants, met the inclusion criteria and were incorporated into our systematic review and meta-analysis. Notable differences in CPP levels were identified across various comparisons. Specifically, CPP levels were significantly elevated in CKD patients compared to healthy controls, with a mean difference (MD) of 12.975 (95% CI 6.572, 19.379). Additional significant MDs were observed in comparisons including controls versus CKD stages 1–2/2 (−1.600 [95% CI −3.179, −0.020]), controls versus CKD stage 3 (−9.598 [95% CI −12.959,−6.237]), controls versus CKD stages 4–5 (−28.776 [95% CI −42.925, −14.628]), and CKD stages 1–2 versus stages 4–5 (−30.475 [95% CI −46.790, −14.160]). <b>Conclusions</b>: Comparison between the CKD patients and healthy controls revealed significantly elevated CPP levels, suggesting a possible role in renal pathology. Furthermore, the distinct differences in CPP concentrations across various CKD stages highlight its potential as a biomarker for assessing disease severity and progression. |
| format | Article |
| id | doaj-art-8295094ec8b34f34ac2f8bf97abb79de |
| institution | OA Journals |
| issn | 2218-273X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-8295094ec8b34f34ac2f8bf97abb79de2025-08-20T02:24:42ZengMDPI AGBiomolecules2218-273X2025-06-0115684510.3390/biom15060845Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-AnalysisGabi Gazi0Robert Cristian Cruciat1Daniel-Corneliu Leucuta2Nahlah Al Srouji3Stefan-Lucian Popa4Mohamed Ismaiel5Dinu Iuliu Dumitrascu6Abdulrahman Ismaiel7Faculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaFaculty of Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaDepartment of Medical Informatics and Biostatistics, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania2nd Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania2nd Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaDepartment of General Surgery, Altnagelvin Hospital, Londonderry BT47 6LS, UKDepartment of Anatomy, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania2nd Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania<b>Background</b>: Numerous studies have explored the potential of the biomarker copeptin (CPP) in diagnosing and assessing the severity of chronic kidney disease (CKD). Despite these efforts, findings have been inconsistent. Consequently, this study aimed to examine the association between CPP and CKD, specifically evaluating its diagnostic value and correlation with CKD severity as classified by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines. <b>Methods</b>: A systematic search of PubMed, EMBASE, and Scopus was conducted using a predefined search string to identify relevant studies. Eligible studies included those involving CKD patients classified by glomerular filtration rate (GFR) according to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines or by the estimated GFR (eGFR) calculated using the MDRD formula, provided they met predefined inclusion criteria. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). The primary outcome measured was the mean difference (MD) in serum CPP levels across the various stages of CKD. <b>Results</b>: A total of seven studies, comprising 2769 participants, met the inclusion criteria and were incorporated into our systematic review and meta-analysis. Notable differences in CPP levels were identified across various comparisons. Specifically, CPP levels were significantly elevated in CKD patients compared to healthy controls, with a mean difference (MD) of 12.975 (95% CI 6.572, 19.379). Additional significant MDs were observed in comparisons including controls versus CKD stages 1–2/2 (−1.600 [95% CI −3.179, −0.020]), controls versus CKD stage 3 (−9.598 [95% CI −12.959,−6.237]), controls versus CKD stages 4–5 (−28.776 [95% CI −42.925, −14.628]), and CKD stages 1–2 versus stages 4–5 (−30.475 [95% CI −46.790, −14.160]). <b>Conclusions</b>: Comparison between the CKD patients and healthy controls revealed significantly elevated CPP levels, suggesting a possible role in renal pathology. Furthermore, the distinct differences in CPP concentrations across various CKD stages highlight its potential as a biomarker for assessing disease severity and progression.https://www.mdpi.com/2218-273X/15/6/845biomarkerchronic kidney diseasecopeptinglomerular filtration rate |
| spellingShingle | Gabi Gazi Robert Cristian Cruciat Daniel-Corneliu Leucuta Nahlah Al Srouji Stefan-Lucian Popa Mohamed Ismaiel Dinu Iuliu Dumitrascu Abdulrahman Ismaiel Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-Analysis Biomolecules biomarker chronic kidney disease copeptin glomerular filtration rate |
| title | Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-Analysis |
| title_full | Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-Analysis |
| title_fullStr | Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-Analysis |
| title_short | Copeptin as a Biomarker in Chronic Kidney Disease—A Systematic Review and Meta-Analysis |
| title_sort | copeptin as a biomarker in chronic kidney disease a systematic review and meta analysis |
| topic | biomarker chronic kidney disease copeptin glomerular filtration rate |
| url | https://www.mdpi.com/2218-273X/15/6/845 |
| work_keys_str_mv | AT gabigazi copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis AT robertcristiancruciat copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis AT danielcorneliuleucuta copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis AT nahlahalsrouji copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis AT stefanlucianpopa copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis AT mohamedismaiel copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis AT dinuiuliudumitrascu copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis AT abdulrahmanismaiel copeptinasabiomarkerinchronickidneydiseaseasystematicreviewandmetaanalysis |